Photo: JUSTIN TALLIS/AFP via Getty Images AstraZeneca (AZN.L ... the proposed deal will need regulatory sign off before it can go ahead. Pascal Soriot, chief executive of AstraZeneca, said: "Alexion ...

Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals ALXN - a company that is best known for its Soliris and Ultomiris drugs which are used to treat rare blood disorders ...

Drugmaker AstraZeneca agreed on Saturday to buy biopharma company Alexion for $39 billion in cash ... hackers who “had free access to their email systems” - NYTimes and WSJ and Bloomberg ...

Leading Covid-19 vaccine developer AstraZeneca agreed on Saturday to buy Boston pharmaceutical firm Alexion (ALXN) for $39 billion. The acquisition is one of the largest deals of the year for the ...

That big “Alexion” sign at the top of the 100 College St. tower? It may soon read “AstraZeneca” instead, as the Cambridge-based drugmaker took one big step closer to a $39 billion takeover of the ...

(Andrew Francis Wallace/Toronto Star via Getty Images) In April 2014 ... Journal reported that the Boston-based Alexion had agreed to be acquired by AstraZeneca for $175 a share — 45% over ...

A little more than a year since its acquisition by AstraZeneca plc, Alexion Pharmaceuticals Inc. is operating in "the best of both worlds" as the official rare disease unit of the U.K. pharma giant.

AstraZeneca's proposed $39bn acquisition of Alexion Pharmaceuticals has been backed by shareholders. At a general meeting, a requisite majority of AstraZeneca shareholders approved the proposal.

Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The acquisition creates ...